๐ฌDeep Research
BMEA โ Biomea Fusion Inc ยท catalysts, narrative & risks
Biomea Fusion, Inc. (Nasdaq: BMEA) โ As of 2026-10-12
Background / positioning
Biomea Fusion is a clinical-stage diabetes and obesity medicines company based in San Carlos, California, focused on oral small-molecule therapies, notably icovamenib (formerly BMF-219, an oral covalent menin inhibitor) and BMF-650 for obesity [2], [6], [13]. It is a micro-cap with a market cap of roughly $102.9M, no revenue, and a stock that has traded between ~$0.87 and $2.24 over the past year [10], [13], [15].
Recent catalysts (last ~1โ3 months)
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ